HTG Molecular Diagnostics, Inc. announced that it has entered into a purchase agreement with Ann Hanham, the Chair of the company's board of directors, pursuant to which it has closed a private placement of one series A preferred stock of par value $0.001 per share for gross proceeds of $100 on October 21, 2022. The preferred share is redeemable, will be entitled to receive dividends on a pari passu basis with the outstanding common shares, and is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the company. The share may not be transferred at any time prior to stockholder approval of a reverse stock split proposal without the prior written consent of the company's board of directors.

The company issued the security pursuant to exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.